This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Femara

Novartis AG

Drug Names(s): Letrozole

Description: Estrogen has been shown to stimulate the growth of certain hormone-dependent cancer cells. In postmenopausal women, estrogen is primarily produced from the conversion of adrenal androgens to estrogen. This conversion is catalyzed by an enzyme known as aromatase. Femara (letrozole) blocks the action of aromatase and therefore inhibits the conversion of androgens to estrogens.

Deal Structure: Chugai and Novartis
In January 2016, Chugai Pharmaceutical announced that Chugai and Novartis Pharma have agreed to terminate the agreement regarding co-marketing of aromatase inhibitor Femara tablets 2.5 mg (generic name: letrozole, hereafter Femara), a treatment for breast cancer after menopause in Japan, as of January 31, 2016.

Novartis Pharma will be solely responsible for the distribution and commercialization of Femara in Japan from February 1, 2016. Chugai and Novartis Pharma will cooperate to accomplish the transition. During the transition period, both companies will maintain the same level of product supply and adequate commercial activities to satisfy any medical needs.


Femara News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug